Jaen Juan C. 4
4 · Arcus Biosciences, Inc. · Filed Jul 13, 2026
Research Summary
AI-generated summary of this filing
Arcus (RCUS) President Juan C. Jaen Sells Shares
What Happened
Juan C. Jaen, President of Arcus Biosciences (RCUS), reported open-market sales totaling 68,569 shares across transactions on July 9–10, 2026. The three reported dispositions were: 48,502 shares at a weighted average $30.05 ($1,457,631), 19,799 shares at a weighted average $28.61 ($566,410), and 268 shares at a weighted average $29.40 ($7,878). Total proceeds were about $2.03 million. These were sales (not purchases) and were made pursuant to a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction dates: July 9, 2026 (48,502 sh @ $30.05); July 10, 2026 (19,799 sh @ $28.61 and 268 sh @ $29.40).
- Total shares sold: 68,569; approximate total proceeds: $2,031,919.
- Price ranges (per footnotes): first sale prices ranged $29.86–$30.57; second sale $28.17–$29.01; third sale $29.30–$29.46. Reported prices are weighted averages; detailed per-share-price breakdowns are available upon request per the filing.
- Footnotes: sales were effected under a Rule 10b5-1 trading plan (F1). Holdings reported in the filing include unvested RSUs (F5).
- Filing: Form 4 was filed July 13, 2026 reporting the July 9–10 transactions; the filing does not indicate a late report.
Context
- These were planned open-market sales under a 10b5-1 plan, which are commonly used by insiders to sell shares on a pre-set schedule and are generally considered routine.
- Sales do not necessarily indicate the insider’s view of the company’s prospects; they report liquidity transactions rather than new investment.
Insider Transaction Report
Form 4
Jaen Juan C.
President
Transactions
- Sale
Common Stock
[F1][F2]2026-07-09$30.05/sh−48,502$1,457,631→ 842,307 total(indirect: By Trust) - Sale
Common Stock
[F1][F3]2026-07-10$28.61/sh−19,799$566,410→ 822,508 total(indirect: By Trust) - Sale
Common Stock
[F1][F4]2026-07-10$29.40/sh−268$7,878→ 822,240 total(indirect: By Trust)
Holdings
- 378,291
Common Stock
[F5]
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]Includes the unvested portion of the Reporting Person's RSU grants.
Signature
/s/ Carolyn Tang, Attorney-in-Fact|2026-07-13